Serina Therapeutics, Inc.

Serina Therapeutics is developing POZ-enabled polymer conjugate therapies using its proprietary POZ (polyoxazoline) platform for CNS diseases including Parkinson's, with SER-252 as a lead asset. Its 100-point trial score spans 25 Phase 1, 28 Phase 2, and 10 Phase 3 studies — substantial late-stage depth for a clinical-stage platform company. Only 2 insider transactions. The POZ polymer platform's potential to improve CNS drug delivery across multiple disease areas makes Serina a platform-level investment thesis worth watching.

<article class="bts-verified-summary" data-ticker="SER">
<p>Serina Therapeutics, Inc. Common Stock (SER) has no currently recruiting or active clinical trials where it is listed as lead sponsor on ClinicalTrials.gov.</p>
<p>SER has 2 Form 4 insider filings recorded at the SEC in the past 30 days<sup><a href="#fn-1">[1]</a></sup>.</p>
<section class="sources" data-nosnippet aria-label="Sources"><h3>Sources</h3><ol><li id="fn-1">SEC EDGAR · 0001708599 (2026-04-11) <a href="https://efts.sec.gov/LATEST/search-index?q=%22SER%22&amp;forms=4&amp;dateRange=custom&amp;startdt=2026-03-12&amp;enddt=2026-04-11" rel="nofollow noopener noreferrer">↗</a></li></ol></section>
</article>